Vertex Pharmaceuticals saw the highest growth of 140% in patent filings in November and 99% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 68% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Vertex Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Vertex Pharmaceuticals has been focused on protecting inventions in United States(US) with one publication in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 0% grants. The United States(US) patent Office are among the top ten patent offices where Vertex Pharmaceuticals is filings its patents.
Pfizer could be the strongest competitor for Vertex Pharmaceuticals
Cystic fibrosis related patents lead Vertex Pharmaceuticals portfolio followed by fibrosis, and pain
Vertex Pharmaceuticals has highest number of patents in cystic fibrosis followed by fibrosis, pain, multiple sclerosis, and diabetes. For cystic fibrosis, nearly 18% of patents were filed and 12% of patents were granted in Q4 2023.
For comprehensive analysis of Vertex Pharmaceuticals's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
